---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-307318"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:37:30.410828+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion receives FDA IND clearance for BMF-219 in type 2 diabetes; expands COVALENT-111 to US sites

## Summary
- FDA cleared IND for BMF-219 (covalent menin inhibitor) in type 2 diabetes; will activate US sites in ongoing COVALENT-111 study.
- Phase I portion completed with favorable safety, PK, and PD profile.
- Phase II portion evaluating BMF-219's ability to restore beta-cell health and long-term glycemic control.
- Initial Phase II data expected in first half of 2023.
- Company to host investor conference call on December 15, 2022 at 4 PM EST.

## SEC filing metadata
- accession: 0001193125-22-307318
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000119312522307318/0001193125-22-307318-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000119312522307318/d426454d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-307318
- JSON: https://secwatch.observer/filing/0001193125-22-307318.json
- Plain text: https://secwatch.observer/filing/0001193125-22-307318.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.